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ABSTRACT 1 
Background: Evidence from animal and in vitro models suggest a role of probiotic bacteria 2 
in improving glycaemic control and delaying the onset of type 2 diabetes. However, the 3 
evidence from controlled trials in humans is limited.  4 
Objective: To determine if the probiotic bacteria L. acidophilus La5 and B. animalis subsp 5 
lactis Bb12, supplemented in a whole food (yoghurt) or isolated (capsules) form, can improve 6 
biomarkers of glycaemic control. 7 
Subjects and methods: Following a 2-week washout period, 156 overweight men and women 8 
over 55 y (mean age: 67 ± 8 years; mean BMI: 31 ± 4 kg/m
2
) were randomized to a 6-week 9 
double-blinded parallel study. The four intervention groups were: A) probiotic yoghurt plus 10 
probiotic capsules; B) probiotic yoghurt plus placebo capsules; C) control milk plus probiotic 11 
capsules; and D) control milk plus placebo capsules. Outcome measurements including 12 
fasting glucose, insulin, glycated haemoglobin and Homeostasis Model Assessment of Insulin 13 
Resistance (HOMA-IR), were performed at baseline and week 6.  14 
Results: Relative to the milk control group, probiotic yoghurt resulted in a significantly 15 
higher HOMA-IR (0.32 ± 0.15, P=0.038), but did not have a significant effect on the other 16 
three measures of glycaemic control (P>0.05). Relative to placebo capsules, probiotic 17 
capsules resulted in a significantly higher fasting glucose (0.15 ± 0.07 mmol/L, P=0.037), 18 
with no significant effect on the other three measures of glycaemic control (P>0.05). Further 19 
analyses did not identify other variables as contributing to these adverse findings. 20 
Conclusions: Data from this study does not support the hypothesis that L. acidophilus La5 21 
and B. animalis subsp lactis Bb12, either in isolated form or as part of a whole food, benefit 22 
short-term glycaemic control. Indeed, there is weak data for an adverse effect of these strains 23 
on glucose homeostasis. 24 
Keywords: Probiotics; yoghurt; dairy products; blood glucose; insulin resistance.  25 
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INTRODUCTION 26 
At a population level, increased glycaemia is associated with increased risk of micro- and 27 
macro-vascular disease (1-4), even in the non-diabetic range (5). Thus population based 28 
approaches to improve glycaemia may reduce adverse vascular outcomes. The pathogenesis 29 
of impaired glucose tolerance and insulin resistance is complex and multifaceted. In addition 30 
to non-modifiable risk factors such as age, genetics and ethnicity, the worldwide epidemic of 31 
excessive body fat due to over-nutrition and physical underactivity, substantially contributes 32 
to type two diabetes prevalence (6-9). Interactions between nutrition and the relative 33 
abundances of genera comprising the over 100 trillion microorganisms residing in the 34 
gastrointestinal tract (10) have also been associated with type two diabetes and related risk 35 
factors (11-17). 36 
Recent experimental data provides impetus for further investigation into the role probiotic 37 
bacteria can play in improving insulin sensitivity and glucose tolerance (18). Probiotic 38 
bacteria are microorganisms which, when administered in adequate amounts, as either 39 
isolated bacteria or in food products, confer a health benefit to the host (19). The most 40 
commonly investigated and verified health benefits of probiotics is their beneficial effect on 41 
gastrointestinal outcomes (20). However, recently the effect of probiotic bacteria on 42 
metabolic outcomes has been studied (21-24).  43 
The role of probiotics in improving glycaemic control has been explored in a RCT of 44 
probiotic supplementation and dietary education in normoglycaemic pregnant women (25). 45 
This study found that in addition to dietary counselling, probiotic supplementation resulted in 46 
significantly lower glucose concentrations and reduced risk of elevated blood glucose level. 47 
Similarly, probiotic supplementation delayed the onset of glucose intolerance, 48 
hyperglycaemia, and hyperinsulinaemia in fructose induced type 2 diabetic rats (26), and 49 
improved long-term glycaemic control in streptozotocin-induced diabetic rats (27). The 50 
glycaemic benefits of probiotics have been attributed to metabolites of these bacteria are 51 
which have been shown to affecting biological signalling pathways, modulate genes involved 52 
in ubiquitination and proteasomal processes, and alter autonomic nerve activity. (28-33). 53 
Overall the evidence from animal models suggests that probiotics may be useful in improving 54 
glycaemic control and delaying onset of type 2 diabetes. However, there is little data to 55 
confirm whether these effects are seen in humans. The proposed study aimed to investigate 56 
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the effects of L. acidophilus La5 and B. animalis subsp lactis Bb12, provided in either 57 
yoghurt or capsules, on biomarkers of glycaemic control in overweight men and women.   58 




Between February 2012 and February 2013, 156 men and women were recruited using a 61 
population-based approach. A random selection of 8,000 men and women aged above 55 62 
years, who were registered on the Western Australian electoral roll, received a letter inviting 63 
them to join the study.  64 
Inclusion criteria included minimal usual probiotic intake (consuming less than 400 g yoghurt 65 
per week, and not taking probiotic supplements), body mass index (BMI) ≥ 25 kg/m
2
, 66 
elevated waist circumference (≥ 94 cm in men and ≥ 80cm in women) and an office blood 67 
pressure ≥ 120/80 mmHg. Exclusion criteria included: inability to complete the study, 68 
intolerance to dairy foods, and the use of antibiotics, immunosuppressive treatments or 69 
hypoglycaemic treatments. Of the 887 respondants screened, 156 were considered eligible 70 
and were randomised into the study (Figure 1). Prespecified sample size calculations 71 
concluded this sample was sufficient to detect a 5% change in fasting glucose concentrations, 72 
with 80% power at P=0.05.  73 
Intervention 74 
Participants were asked to cease consumption of all foods and products containing probiotic 75 
bacteria during both the 3-week washout and 6-week intervention periods. Following 76 
washout, subjects were allocated to 1 of 4 study treatments via block randomization using 77 
computer-generated random numbers, devised by a statistician.  Participants were assigned to 78 
receive either: A) probiotic yoghurt plus probiotic capsules; B) probiotic yoghurt plus 79 
placebo capsules; C) control milk plus probiotic capsules; or D) control milk plus placebo 80 
capsules. Dairy products and capsules were consumed once daily, 30 minutes prior to the first 81 
meal of the day.  82 
Both the probiotic yoghurt and probiotic capsules provided a minimum Lactobacillus 83 
acidophilus La5 and Bifidobacterium animalis subsp lactis Bb12 dose of 3.0 x 10
9
 CFU/d. 84 
All capsules were identical in appearance, size, and colour and were prepared by Chr Hansen 85 
(Australia). The probiotic yoghurt (prepared by Casa Dairy Products, Australia) and control 86 
milk (prepared by Harvey Fresh, Australia) were similar in their nutritional composition. 87 
Participants in the control milk group received 8 g protein, 720 kJ, 4 g saturated fat, 12 g 88 
carbohydrate. Similarly, participants in the probiotic yoghurt group received 9 g protein, 89 
650 kJ, 4 g saturated fat, 9 g carbohydrate from yoghurt per day.  90 
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Written informed consent was obtained in 100% of participants, and the Human Research 91 
Ethics Committee of the University of Western Australia, Perth, Australia, approved the 92 
study. The study was carried out in accordance with the World Medical Association 93 
Declaration of Helsinki, and was registered with the Australian New Zealand Clinical Trials 94 
Registry prior to recruitment (ACTRN12612000033842). All data was collected at Sir 95 
Charles Gairdner Hospital, Perth, Australia. 96 
Compliance 97 
Compliance was assessed by counting remaining capsules and weighing remaining dairy 98 
product at the completion of the study. Adherence was further assessed by a compliance diary 99 
whereby participants kept a daily log of test article consumption throughout the intervention 100 
period.  101 
Baseline measurements 102 
At the end of the washout (baseline) standing height was measured by a wall-mounted 103 
stadiometer to the nearest 0.1cm, and body weight was measured by an electronic scale to the 104 
nearest 0.1 kg. Body mass index was calculated in kg/m
2
. Waist circumference was measured 105 
by a tape measure to the nearest 0.1 cm at the narrowest part of the torso from the ventral 106 
view. 107 
Dietary intake was assessed by a validated semi-quantitative food frequency questionnaire 108 
developed by the Anti-Cancer Council of Victoria (34). Energy and nutrient intakes were 109 
estimated based on frequency of consumption and an overall estimate of usual portion size 110 
(35), and the glycaemic load of the diet was estimated based on published values (36). The 111 
international Physical Activity Questionnaire was used to estimate the weekly energy 112 
expended in physical tasks, as represented by the metabolic equivalent of task (MET) 113 
score (37). 114 
Measurements of glycaemic control 115 
Fasting blood glucose, insulin and glycated haemoglobin (HbA1c) concentrations were 116 
assessed at the end of the washout (baseline) and at end of the 6-week intervention period 117 
(week 6). 118 
In order to determine effects of the intervention on longer term glycaemic control (38), 119 
HbA1c was measured by the Tina-quant Haemoglobin A1c Gen2 whole blood application 120 
(Roche Diagnostics for Integra 800 - [A1C-W, 2007-01, V 3]).  121 
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Serum glucose was measured by the Architect c16000 Analyser and serum insulin was 122 
measured on the Architect i2000SR Analyser. Glucose and insulin reagents were obtained 123 
from Abbott Diagnostics (Abbott Laboratories, Abbott Park, IL 60064, USA). In order to 124 
determine the effect of the intervention on the responsiveness of peripheral tissues to insulin 125 
action, the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was calculated 126 
with the following formula: fasting serum insulin (mU/ml) x fasting plasma glucose 127 
(mmol/l) / 22.5 (39). 128 
Blinding and statistical analysis  129 
Participants were allocated to a study treatment via block randomization, using computer-130 
generated random numbers (generated by a biostatistician who was not involved in the 131 
conduct of the study) sealed in opaque envelopes. All study personnel and participants were 132 
blinded to treatment assignment for the duration of the study. A senior investigator not 133 
involved in trial implementation held the randomisation code in a password protected folder, 134 
which was not broken until the trial had been completed and the analytical protocol had been 135 
finalised. All data was analysed according to a pre-specified protocol using SPSS (PASW 136 
version 18; IBM Corp., New York, NY, USA).  137 
The week-6 fasting glucose, insulin, glycated haemoglobin and HOMA-IR were compared 138 
across intervention groups using a multivariable regression model, with adjustment for the 139 
baseline levels of each outcome, and for the effect of the other intervention (40).  140 
As a secondary analysis, the interaction between probiotic yoghurt and probiotic capsules 141 
was explored. Further multivariable regression analyses, adjusting for changes (week-6 – 142 
Baseline) in BMI, waist circumference, physical activity level, glycaemic load, and intakes of 143 
energy, fat, carbohydrate and protein, were undertaken in order to explore factors which may 144 
contribute to the findings.   145 
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RESULTS 146 
Participant characteristics and compliance 147 
A total of 60 women and 96 men were randomised (Figure 1), with a mean age of 67 ± 8 148 
years and a mean BMI of 31 ± 4 kg/m
2
. During the 6-week intervention, 5 participants 149 
withdrew from the study: 2 due to a death in the family, and 3 due to illnesses which did not 150 
appear to be as a result of the dairy products or capsules. Throughout the study period, all 151 
participants remained free of hypoglycaemic agent use, and median compliance was 100%.
 
152 
Treatment groups were well matched at baseline (Table 1), and there were no significant 153 
differences between groups for age, sex, BMI, waist circumference, physical activity level, 154 
and dietary intake variables (P>0.05). Similarly, the biomarkers of glycaemic control 155 
(Table 2) were not different between intervention groups at baseline (P>0.05). A total of 5 156 
(3%) of participants had a HbA1c value greater than 6.5 % at baseline.  157 
Effect of intervention on biomarkers of glycaemic control 158 
Probiotics from yoghurt or capsules did not significantly alter concentrations of either 159 
glycated haemoglobin or insulin relative to control treatments (Table 3). Probiotic yoghurt 160 
resulted in higher HOMA-IR (Table 3), whilst probiotic capsules did not significantly alter 161 
HOMA-IR (Table 4). Probiotic capsules resulted in higher fasting glucose concentration 162 
(Table 4), whereas probiotic yoghurt did not significantly alter fasting glucose (Table 3). 163 
Exploratory analyses 164 
The interaction between the interventions was investigated as a secondary analysis, and was 165 
found to be non-significant: interaction coefficient (HbA1c) = 0.001 (P=0.978); interaction 166 
coefficient (glucose) = 0.027 (P=0.871); interaction coefficient (insulin) = 0.684 (P=0.410); 167 
interaction coefficient (HOMA-IR) = 0.443 (P=0.507). As such, the observed effects of 168 
probiotic yoghurt and probiotic capsules did not appear to be influenced by the presence or 169 
absence of the other probiotic test article.  170 
In order to assess how overall glycaemic control at baseline, as assessed by HbA1c, affects 171 
responsiveness to the probiotic interventions, we explored the interaction between the 172 
interventions and HbA1c. Inclusion of baseline HbA1c in the multivariable regression models 173 
did not alter interpretation of results (data not shown). 174 
In order to identify factors which may explain observed results, the degree in which the 175 
hyperglycaemia risk factors changed during the intervention period were adjusted for in 176 
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multivariable regression analyses. Inclusion of these variables in the models did not 177 
ameliorate or exacerbate the effect of the interventions on glycaemic outcomes. Furthermore, 178 
we did not observe any significant difference across treatment groups in change (Week 6 – 179 
Baseline) of the modifiable risk factors outlined in Table 1 (data not shown).   180 
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DISCUSSION 181 
Although data from animal studies suggest mechanisms whereby probiotics may benefit 182 
glycaemic control and insulin sensitivity (28-30), the present study suggests that 183 
supplementation with L. acidophilus La5 and B. animalis subsp lactis Bb12 does not improve 184 
glycaemic control, and may indeed have a slight detrimental effect.  185 
When compared to the appropriate control, capsules containing L. acidophilus La5 and B. 186 
animalis subsp lactis Bb12 marginally increased glycaemia, probiotic yoghurt increased 187 
insulin resistance, and no statistically significant effect on other biomarkers of glycaemic 188 
control was observed. These results are in contrast to the animal studies and other human trial 189 
data that suggest an acute and long-term hypoglycaemic effect of probiotic bacteria (25-27). 190 
However, our results are in keeping with data from other human randomised controlled trials 191 
demonstrating no effect of probiotic bacteria on glycaemia (41-43). The discrepancy between 192 
findings from human and animal trials may be due to innate biological differences between 193 
species, and the subsequent differences in maintenance of glucose homeostasis.  194 
In this regard, the complexity of beneficial and detrimental probiotic-microbiome-host 195 
interactions should be recognised (44). In addition to increasing probiotic levels in the 196 
gastrointestinal tract, supplementation of probiotic bacteria can also result in proportional 197 
reductions in other genera (45). Furthermore, the activities of probiotic bacteria are highly 198 
variable and influenced by numerous factors. Gene expression of probiotic bacteria is not 199 
only affected by interactions with other bacteria residing in the gastrointestinal tract, but by 200 
the genotype of the host (46). This metabolic variance is further complicated by the effect 201 
host diet has on probiotic metabolism (47). The numerous factors affecting probiotic 202 
metabolism and activity, and the numerous factors probiotic bacteria impact on are not yet 203 
fully understood, and may explain why in this study, L. acidophilus La5 and B. animalis 204 
subsp lactis Bb12 did not exert the hypothesised effects. 205 
Another explanation for the discordance between findings from this and other studies may lie 206 
with the variations in study design. Studies observing glycaemic benefits of probiotic 207 
supplementation used models of induced diabetes or naturally occurring insulin resistance 208 
during pregnancy (25-27). Gestational state, although associated with insulin resistance, is 209 
almost certainly fundamentally different in physiology compared to non-pregnant individuals, 210 
primarily due to the variety of differences in hormonal status (48-50). In concert with the 211 
other negative probiotic studies (41-43), this cohort largely exhibited good glycaemic control. 212 
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Therefore, despite not observing a mediating association of baseline long term glycaemic 213 
control in this primarily healthy population, we hypothesise that the beneficial effects of 214 
probiotics may be limited to pathological states of insulin resistance or type 2 diabetes.  215 
An important but often overlooked factor affecting both metabolic outcomes and ability of 216 
the bacteria colonise the gastrointestinal tract, is the bacterial strain and combinations of 217 
strains used in probiotic products (51). To date, all the animal and human studies of 218 
probiotics on glycaemia have used different strains, combinations of strains or doses of 219 
probiotic bacteria, which may help explain the variation in reported glycaemic effects. A 220 
strength of this study design is that in addition to being commonly used in the yoghurt and 221 
supplement industries, the strains L. acidophilus La5 and B. animalis subsp lactis Bb12 used 222 
in this study were chosen due to their demonstrated capacity to survive the harsh environment 223 
of the human gastrointestinal tract (52-54), adhere to hydrocarbons (55, 56), and exert 224 
metabolic benefits (23). However, despite this, glycaemic benefits of these strains were not 225 
observed. 226 
We found that probiotic capsules and probiotic yoghurt had different effects on glycaemic 227 
biomarkers. The fasting glucose concentration was significantly higher in the participants 228 
taking probiotic capsules, but not the probiotic yoghurt group. The HOMA-IR was 229 
significantly higher in the participants consuming probiotic yoghurt group, but not the 230 
probiotic capsules group. This apparent discrepancy in effects of probiotic yoghurt and 231 
capsules may be due to either a Type I or type II statistical error. A post-hoc power 232 
calculation showed that the study had only 9% power to detect the observed difference in 233 
HOMA-IR for probiotic capsules, and 22% power to detect the observed difference in fasting 234 
glucose for probiotic yoghurt. Thus, it may be that there is a negative effect of probiotics on 235 
glycaemia, but the effect size is so small that we were underpowered to detect it. 236 
In conclusion, data from this study does not support the hypothesis that L. acidophilus La5 237 
and B. animalis subsp lactis Bb12, either in isolated form or incorporated into a whole food, 238 
benefit short-term glycaemic control in men and women. The effect of probiotic bacteria on 239 
metabolism is complex due to both the complexity of host-microbiome interactions and the 240 
complexity of strains of probiotic bacteria. Future replication studies, particularly in diabetic 241 
patients, are indicated in order to clarify the role of probiotic strains on glycaemic control.   242 
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Figure 1: Trial profile. 
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Table 1: Baseline characteristics by treatment group. 
 
   
Dairy test article Probiotic yoghurt Control milk 
Capsule test article  Probiotic Placebo Probiotic Placebo 
 Group A Group B Group C Group D 
     
Number 40 37 39 40 
     
Age (years)
 
68.4 ± 7.8 68.4 ± 8.7 64.7 ± 7.1 65.4 ± 8.4 





30.6 ± 3.8 30.2 ± 4.3 30.8 ± 3.5 30.8 ± 3.5 
Waist circumference (cm) 103 ± 10 101 ± 12 100 ± 9 100 ± 9 
Physical activity (MET)  111 ± 7 109 ± 8 109 ± 8 111 ± 6 
Energy intake (kJ/d) 7590 ± 2649 7473 ± 2433 8199 ± 2505 7367 ± 2299 
Glycaemic load 83 ± 35 87 ± 33 94 ± 33 81 ± 34 
Fat intake (g/d) 69 ± 26 73 ± 29 81 ± 29 72 ± 27 
Carbohydrate intake (g/d) 169 ± 66 171 ± 60 187 ± 59 166 ± 64 
Protein intake (g/d) 87 ± 31 94 ± 29 94 ± 35 85 ± 29 
     
1 
Results are mean ± SD or n where appropriate. 
No significant between group differences were identified by ANOVA (P>0.05). 
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Table 2: Treatment group summary statistics of glycaemic parameters at baseline and 
6-weeks. 
 
   
Dairy test article Probiotic yoghurt Control milk 
Capsule test article  Probiotic Placebo Probiotic Placebo 
 Group A Group B Group C Group D 
     
Number 40 37 39 40 
 
Fasting glucose  
    
   Baseline (mmol/L)  5.53 ± 0.57 5.64 ± 1.01 5.59 ± 1.15 5.36 ± 0.55 
   Week 6 (mmol/L) 5.62 ± 0.65 5.47 ± 0.73 5.58 ± 1.29 5.18 ± 0.65 
   Change (mmol/L) 0.08 ± 0.39 -0.07 ± 0.43 -0.04 ± 0.36 -0.17 ± 0.50 
 
Fasting insulin 
    
   Baseline (mU/ml) 9.93 ± 4.75 9.63 ± 4.82 9.77 ± 4.59 9.99 ± 4.49 
   Week 6 (mU/ml) 11.20 ± 5.27 10.59 ± 6.74 9.74 ± 4.56 10.18 ± 5.36 
   Change (mmol/L) 1.32 ± 2.76 0.63 ± 3.83 -0.18 ± 3.33 0.18 ± 4.22 
 
HOMA-IR 
    
   Baseline  2.47 ± 1.27 2.48 ± 1.45 2.45 ± 1.18 2.44 ± 1.29 
   Week 6  2.85 ± 1.52 2.63 ± 1.91 2.41 ± 1.17 2.38 ± 1.39 
   Change (mmol/L) 0.39 ± 0.75 0.15 ± 1.04 -0.05 ± 0.87 -0.05 ± 1.011 
     
HbA1c      
   Baseline (%) 5.74 ± 0.41 5.86 ± 0.65 5.83 ± 0.67 5.56 ± 0.36 
   Week 6 (%) 5.69 ± 0.33 5.74 ± 3.19 5.78 ± 0.64 5.60 ± 0.34 
   Change (mmol/L) -0.05 ± 0.28 -0.04 ± 0.23 -0.05 ± 0.28 0.28 ± 0.28 
     
Results are mean ± SD. 
No significant between group differences were identified by ANOVA (P>0.05). 
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Table 3: Main effect model of probiotic yoghurt supplementation on biomarkers of glycaemic 
control at 6-weeks. 
 
     
 Probiotic yoghurt
1
 Baseline adjusted difference
2
 P value 
 No Yes  
     
Number 79 77   
     
HbA1c (%) 5.71 ± 0.03 5.69 ± 0.03 -0.02 ± 0.04 0.710 
Glucose (mmol/L)
 
5.40 ± 0.05 5.52 ± 0.05 0.12 ± 0.07 0.094 




2.43 ± 0.10 2.75 ± 0.11 0.32 ± 0.15 0.038 
1
 Results are week 6 mean (± SE), adjusted for baseline values and treatment. 
2
 Mean difference (± SE) between yes and no.   
The interaction between the interventions was found to be non-significant (P>0.05). 
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Table 4: Main effect model of probiotic capsule supplementation on biomarkers of glycaemic 
control at week 6. 
 
     
 Probiotic capsule
1
  Baseline adjusted difference
2
 P value 
 No Yes  
     
Number 77 79   
     
HbA1c (%) 5.71 ± 0.03 5.69 ± 0.03 -0.02 ± 0.04 0.705 
Glucose (mmol/L)
 
5.39 ± 0.05 5.54 ± 0.05 0.15 ± 0.07 0.037 




2.53 ± 0.11 2.65 ± 0.10 0.12 ± 0.15 0.419 
1
 Results are week 6 mean (± SE), adjusted for baseline values and treatment. 
2
 Mean difference (± SE) between yes and no.  
The interaction between the interventions was found to be non-significant (P>0.05). 
 
 
 
 
